The mRNA expression profile of cytokines connected to the regulation of melanocyte functioning in vitiligo skin biopsy samples and peripheral blood mononuclear cells

Human Immunology

Volumn 73, Issue 4, 2012, Pages 393-398

  Reimann, Ene ^a   Kingo, Külli ^a   Karelson, Maire ^a   Reemann, Paula ^a   Loite, Ulvi ^a   Sulakatko, Helen ^a   Keermann, Maris ^a   Raud, Kristi ^a   Abram, Kristi ^a   Vasar, Eero ^a,b   Silm, Helgi ^a   Kõks, Sulev ^a,b  

^a UNIVERSITY OF TARTU   (Estonia)

^b ESTONIAN UNIVERSITY OF LIFE SCIENCES   (Estonia)

Author keywords

Gene expression; IL 10 family cytokines; Melanocytes; Pro inflammatory cytokines; Vitiligo

Indexed keywords

ALPHA1 INTERFERON; BETA1 INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 20B RECEPTOR; INTERLEUKIN 22; INTERLEUKIN 22A RECEPTOR; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 28A; INTERLEUKIN 28A RECEPTOR; INTERLEUKIN 28B; INTERLEUKIN 29; INTERLEUKIN RECEPTOR; MDM1 PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERFERON GAMMA RELEASE ASSAY; MALE; MELANOCYTE; MELANOGENESIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; VITILIGO;

ADULT; AGED; BIOPSY; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MELANOCYTES; MIDDLE AGED; RNA, MESSENGER; SKIN; VITILIGO; YOUNG ADULT;

EID: 84859109012     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.01.011     Document Type: Article

References (38)

1. Kemp E.H., Waterman E.A., Weetman A.P. Autoimmune aspects of vitiligo. Autoimmunity 2001, 34:65-77.
2. Ongenae K., Van Geel N., Naeyaert J.M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003, 16:90-100.
3. Castanet J., Ortonne J.P. Pathophysiology of vitiligo. Clin Dermatol 1997, 15:845-851.
4. Honda Y., Okubo Y., Koga M. Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo. J Dermatol 1997, 24:561-563.
5. Yu H.S., Chang K.L., Yu C.L., Li H.F., Wu M.T., Wu C.S., et al. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997, 108:527-529.
6. Caixia T., Hongwen F., Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999, 21:59-62.
7. Moretti S., Spallanzani A., Amato L., Hautmann G., Gallerani I., Fabiani M., et al. New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002, 15:87-92.
8. Zailaie M.Z. Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. Saudi Med J 2005, 26:799-805.
9. Grimes P.E. White patches and bruised souls: Advances in the pathogenesis and treatment of vitiligo. J Am Acad Dermatol 2004, 51(1 Suppl):S5-S7.
10. Renauld J.C. Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators. Nat Rev Immunol 2003, 3:667-676.
11. Sheikh F., Baurin V.V., Lewis-Antes A., Shah N.K., Smirnov S.V., Anantha S., et al. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol 2004, 172:2006-2010.
12. Xu W., Presnell S.R., Parrish-Novak J., Kindsvogel W., Jaspers S., Chen Z., et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A 2001, 98:9511-9516.
13. Nagalakshmi M.L., Murphy E., McClanahan T., de Waal Malefyt R. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol 2004, 4:577-592.
14. Uzé G., Monneron D. IL-28 and IL-29: Newcomers to the interferon family. Biochimie 2007, 89:729-734.
15. Grimes P.E., Morris R., Avaniss-Aghajani E., Soriano T., Meraz M., Metzger A. Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004, 51:52-61.
16. Rätsep R., Kingo K., Karelson M., Reimann E., Raud K., Silm H., et al. Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. Br J Dermatol 2008, 159:1275-1281.
17. Badciong J.C., Haas A.L. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002, 277:49668-49675.
18. Xiong S., Van Pelt C.S., Elizondo-Fraire A.C., Liu G., Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A 2006, 103:3226-3231.
19. Stark G.R., Fau-Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264.
20. Bielenberg D.R., McCarty M.F., Bucana C.D., Yuspa S.H., Morgan D., Arbeit J.M., et al. Expression of interferon-beta is associated with growth arrest of murine and human epidermal cells. J Invest Dermatol 1999, 112:802-809.
21. Satomi H., Wang B., Fujisawa H., Otsuka F. Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. Cytokines 2002, 18:108-115.
22. Lu G., Shimizu I., Cui X., Itonaga M., Tamaki K., Fukuno H., et al. Interferon-alpha enhances biological defense activities against oxidative stress in cultured rat hepatocytes and hepatic stellate cells. J Med Invest 2002, 49:172-181.
23. Seçkin D., Durusoy C., Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 2004, 21:577-579.
24. Miller R.L., Tomai M.A., Harrison C.J., Bernstein D.I. Immunomodulation as a treatment strategy for genital herpes: Review of the evidence. Int Immunopharmacol 2002, 2:443-451.
25. Qin X.Q., Beckham C., Brown J.L., Lukashev M., Barsoum J. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther 2001, 4:356-364.
26. Francois D.T., Katona I.M., June C.H., Wahl L.M., Mond J.J. Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Clin Immunol Immunopathol 1988, 48:297-306.
27. Passeron T., Ortonne J.P. Physiopathology and genetics of vitiligo. J Autoimmun 2005, 25(Suppl):63-68.
28. Kocer B., Nazliel B., Oztas M., Batur H.Z. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: A case report. Eur J Neurol 2009, 16:e78-e79.
29. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007, 96:41-101.
30. Hedley S.J., Metcalfe R., Gawkrodger D.J., Weetman A.P., Mac Neil S. Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules. Br J Dermatol 1998, 139:965-973.
31. Ahn S.K., Choi E.H., Lee S.H., Won J.H., Hann S.K., Park Y.K. Immunohistochemical studies from vitiligo-comparison between active and inactive lesions. Yonsei Med J 1994, 35:404-410.
32. al Badri A.M., Foulis A.K., Todd P.M., Gariouch J.J., Gudgeon J.E., Stewart D.G., et al. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 1993, 169:203-206.
33. Ogg G.S., Rod Dunbar P., Romero P., Chen J.L., Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998, 188:1203-1208.
34. Witte K., Gruetz G., Volk H.D., Looman A.C., Asadullah K., Sterry W., et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: Implications for therapeutic applications of these cytokines. Genes Immun 2009, 10:702-714.
35. Snyder L.C., Trusko S.P., Freeman N., Eshleman J.R., Fakharzadeh S.S., George D.L. A gene amplified in a transformed mouse cell line undergoes complex transcriptional processing and encodes a nuclear protein. J Biol Chem 1988, 263:17150-17158.
36. Chang B., Mandal M.N., Chavali V.R., Hawes N.L., Khan N.W., Hurd R.E., et al. Age-related retinal degeneration (arrd2) in a novel mouse model due to a nonsense mutation in the Mdm1 gene. Hum Mol Genet 2008, 17:3929-3941.
37. Yagi H., Tokura Y., Furukawa F., Takigawa M. Vitiligo with raised inflammatory borders: Involvement of T cell immunity and keratinocytes expressing MHC class II and ICAM-1 molecules. Eur J Dermatol Clin 1997, 7:19-22.
38. Le Poole I.C., van den Wijngaard R.M., Westerhof W., Das P.K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996, 148:1219-1228.